When you’ve been told you need surgery for bile duct cancer (cholangiocarcinoma) – preparing as a patient
For patients, families, and primary care teams. From the team behind prehabforsurgery.com.
Cholangiocarcinoma – bile duct cancer, often shortened to CCA – is uncommon but serious. It arises from the cells lining the bile ducts, the network of tubes that drain bile from the liver into the small intestine. There are three main subtypes depending on where in that network the cancer starts: intrahepatic (within the liver itself), perihilar (at the confluence where the right and left bile ducts meet – also called Klatskin tumours), and distal (lower in the bile duct, closer to where it enters the duodenum).
If you have just been told you need surgery for cholangiocarcinoma, the next few weeks will involve more clinical activity than most surgical pathways: biliary drainage, detailed imaging and sometimes endoscopic procedures, a multidisciplinary review involving HPB surgeons, hepatologists, oncologists, and interventional radiologists. The disease is complex; the preparation for surgery is correspondingly intensive.
Honest framing first: outcomes for CCA are more guarded than for some other liver cancers, because the disease is often diagnosed at a more advanced stage and because the anatomy makes complete surgical clearance technically demanding. But for the roughly one in three patients who are resectable, surgical removal at a specialist HPB centre is the single best chance of long-term survival, and modern systemic therapy has materially improved options for those whose disease cannot be removed. This article walks through what CCA is, how the team decides between surgical and non-surgical paths, and what you can do in the weeks before surgery to give yourself the best possible chance. It is not a substitute for advice from your own team – it is a starting point for the conversations that follow.
New to prehab? Start with our complete guide to what prehab is.
The three subtypes of cholangiocarcinoma
The location of the tumour within the bile duct network shapes everything about treatment. Three subtypes are recognised:
Intrahepatic cholangiocarcinoma (iCCA)
Arises in the small bile ducts within the liver itself. Often presents as a liver mass on imaging and can be mistaken for HCC or for liver metastases from another cancer. Treated primarily with liver resection (hepatectomy), similar in approach to other liver surgeries. Around 10-20% of all cholangiocarcinomas globally.
Perihilar cholangiocarcinoma (pCCA) – Klatskin tumour
Arises at the bile duct confluence – where the right and left hepatic ducts meet to form the common hepatic duct. The most common subtype (50-60% of all CCA) and the most technically challenging to remove. Surgical resection typically requires removal of the affected side of the liver PLUS the bile duct confluence PLUS reconstruction of the remaining biliary drainage – a major operation undertaken only in specialist HPB centres. Klatskin tumours are classified by the Bismuth-Corlette system (Types I to IV) based on how far the tumour extends up into the bile duct branches.
Distal cholangiocarcinoma (dCCA)
Arises in the lower bile duct, in the segment that runs through the head of the pancreas before entering the duodenum. Treated similarly to pancreatic head cancer – typically with Whipple’s procedure (pancreaticoduodenectomy). Roughly 20-30% of all CCA.
If your CCA is distal, the existing Whipple preparation guide on this site covers most of the surgical and prehab considerations relevant to you – this current article focuses primarily on the intrahepatic and perihilar subtypes, where the surgery is a liver resection rather than a Whipple.
What modern outcomes look like – honest figures
Outcomes vary substantially by subtype, by resectability, and by lymph node status. Realistic figures from contemporary large series at specialist centres:
• Resectable iCCA – 5-year survival after R0 resection: 25-40%. Survival drops materially if lymph nodes are involved or if margins are positive.
• Resectable pCCA (Klatskin) – 5-year survival after R0 resection with negative lymph nodes: 30-45%; less good if nodes positive or if margin involvement.
• Resectable dCCA – 5-year survival 25-35% (similar range to pancreatic head cancer).
• Unresectable but locally-advanced disease treated with modern chemo-immunotherapy (durvalumab + gemcitabine/cisplatin per TOPAZ-1 or pembrolizumab + gem/cis per KEYNOTE-966): median overall survival 12-14 months – modest improvement over chemo alone but the first meaningful change in the systemic-therapy landscape in over a decade.
• Targeted therapy options now exist for selected iCCA with FGFR2 fusions (pemigatinib, futibatinib, infigratinib) or IDH1 mutations (ivosidenib) – molecular profiling at diagnosis is increasingly standard and can open additional treatment pathways.
These figures are sobering compared to CRLM or HCC, but they are also dramatically better than the figures from even ten years ago. The combination of better surgical patient selection, routine adjuvant chemotherapy (capecitabine post-resection per BILCAP), and modern systemic options for unresectable disease has measurably moved the dial. Treatment at a specialist HPB centre with a dedicated cholangiocarcinoma MDT consistently outperforms general-cancer-centre management.
Who is suitable for surgery?
Three questions, similar in shape to HCC and CRLM decisions but with cholangiocarcinoma-specific nuances:
1. Is the tumour anatomically resectable?
For iCCA: similar to other liver cancers – can the tumour be removed with negative margins while leaving enough functional liver behind? Lymph node involvement (in the porta hepatis or beyond) significantly worsens outcomes and may shift the decision toward neoadjuvant chemotherapy first.
For pCCA (Klatskin): how far does the tumour extend up into the right or left ducts? Bismuth-Corlette classification matters. Type I and II tumours are usually resectable; Type IIIa requires extended right hepatectomy; Type IIIb requires extended left hepatectomy; Type IV (involving both sides) is often unresectable but transplant is being explored in selected centres. Vascular involvement (portal vein or hepatic artery) does NOT automatically preclude resection in expert hands – vascular resection and reconstruction is technically demanding but feasible at high-volume centres.
For dCCA: covered in the Whipple guide; resectability depends on the same vascular criteria as for pancreatic head cancer (SMV/portal vein involvement may still be resectable; SMA or coeliac involvement usually not).
2. Is the remaining liver healthy enough?
Less of an issue than in HCC because most cholangiocarcinoma patients do not have underlying chronic liver disease – but patients with primary sclerosing cholangitis (a known risk factor for cholangiocarcinoma) often have advanced liver disease from the PSC itself, which complicates resection planning significantly.
3. Is the patient overall fit enough?
Same considerations as for any major hepatobiliary surgery – performance status, comorbidities, nutritional state. Cholangiocarcinoma patients are frequently jaundiced and malnourished at diagnosis, both of which need addressing pre-operatively.
The pre-operative assessment journey – typically more involved than other liver cancers
If surgery is on the table, expect:
• Detailed imaging – triphasic CT and MRI with MRCP (magnetic resonance cholangiopancreatography) for biliary anatomy; sometimes additional PET-CT to assess for distant disease
• Tumour markers – CA 19-9 (most relevant); CEA in some cases
• Biliary drainage if jaundiced – typically endoscopic via ERCP (stent placement) or, when ERCP is not technically feasible, percutaneous transhepatic cholangiography (PTC) with drain placement. Drainage is to reduce serum bilirubin below 50 µmol/L (3 mg/dL) before major hepatectomy – this is critically important because operating on a deeply jaundiced patient carries substantially higher risks of post-op liver failure and infection
• Tissue diagnosis – sometimes biopsy is needed pre-operatively (particularly for iCCA to distinguish from HCC), sometimes the diagnosis is made on the resection specimen alone
• Molecular profiling – increasingly standard for iCCA (FGFR2 fusions, IDH1/IDH2 mutations, BRAF, HER2, MSI status) – opens future targeted therapy options if needed
• Cardiopulmonary exercise testing (CPET) – standard pre major hepatectomy
• Specialist anaesthetic assessment
• Nutritional assessment by dietitian – frequently essential; many CCA patients are significantly malnourished and benefit from pre-operative nutritional rehabilitation
• Portal vein embolisation (PVE) – for major hepatectomies where future liver remnant volume is borderline
• Multidisciplinary review including HPB surgery, hepatology, medical oncology, interventional radiology, and pathology
This work-up can take 4–8 weeks – longer than for many other liver cancers because of the biliary drainage piece, the need for sequential imaging after drainage, and the time to allow bilirubin to normalise. Use this window actively for prehab.
Prehab for cholangiocarcinoma – what’s specific to your situation
1. Biliary drainage management – the most CCA-specific piece
If you have an ERCP stent or a PTC drain in place, learn how to look after it. Specific things to do or be aware of:
• Recognise cholangitis early – fever, rigors, jaundice worsening, abdominal pain (the classic Charcot triad of fever + jaundice + RUQ pain is the textbook presentation but not always all three are present). Contact your team immediately if any of these develop – cholangitis is the most common pre-op complication and can delay surgery if not promptly treated.
• PTC drain care: keep the dressing dry and clean; monitor the volume and colour of drainage; never disconnect the bag without checking first with your team. If drainage suddenly stops or output drops materially, contact your team – it may indicate blockage.
• Stent issues: occluded stents present as recurrent jaundice or cholangitis and may need re-ERCP for replacement.
• Track your bilirubin trend – your team will be checking weekly. Surgery is typically delayed until bilirubin is below 50 µmol/L (3 mg/dL) and ideally trending toward normal. Ask what your numbers are at each visit.
2. Nutrition – usually the second-biggest priority
Many CCA patients have lost significant weight by the time of diagnosis, both from the tumour itself and from the cholestasis-related malabsorption that comes with biliary obstruction. Aggressive nutritional rehabilitation pre-op materially improves surgical outcomes.
• Aim for 1.5g protein/kg/day – palm-sized protein at each meal plus protein snacks
• Oral nutritional supplements (Ensure, Fortisip, Fresubin) commonly prescribed – these are genuinely useful, not just a marketing tool
• Fat absorption is often impaired due to biliary diversion or obstruction – your dietitian may recommend medium-chain triglyceride (MCT) supplements, which absorb without bile acids
• Fat-soluble vitamin levels (A, D, E, K) – often very low in obstructive jaundice patients; supplementation usually needed
• Vitamin K status particularly important – long-standing obstruction depletes vitamin K, prolongs INR, and increases bleeding risk
• If malnutrition is severe and oral intake is inadequate, your team may recommend 7-14 days of nasojejunal feeding or even short-term TPN before surgery
3. Cardiopulmonary fitness
Same as for other major liver surgery – even 3-4 weeks of structured walking 30-45 min/day improves outcomes. CCA patients may have less stamina than other surgical candidates because of the underlying disease – work within what your team thinks is safe but do something every day.
4. Smoking and alcohol cessation
Stop smoking ≥8 weeks pre-op, alcohol ≥4 weeks. Both materially affect liver regeneration and wound healing. Standard advice but particularly important given the major nature of CCA surgery.
5. Anaemia and iron
Many CCA patients are anaemic from chronic disease and from any prior biliary procedure-related blood loss. Iron infusion (ferric carboxymaltose) in the 2-4 weeks pre-op substantially reduces the likelihood of needing transfusion intra-operatively. Ask if iron studies and ferritin have been checked.
6. Diabetes optimisation
Some CCA patients have new-onset diabetes from the pancreatic compression (particularly with distal tumours) or from longstanding cholestasis. Optimisation per the same standards as for other major surgery – HbA1c <64 mmol/mol (8%) ideally before operating.
7. Vigilance against cholangitis between drainage and surgery
Cholangitis is the most common pre-op complication and is the leading cause of surgical delay or cancellation. Know the signs, know the threshold for contacting your team (any fever – do not wait), and keep a low-grade vigilance throughout the pre-op window. Many centres prescribe prophylactic antibiotic cover for patients with indwelling biliary drainage – clarify with your team what they recommend for your specific situation.
8. Practical preparation at home
• Help at home for at least 4-6 weeks post-discharge – major hepatobiliary surgery recovery is typically slower than other major surgeries due to drain management, biliary leak monitoring, and slower return of GI function
• Stock the freezer with high-protein, easy-prepare meals; consider low-fat options if your team has advised this post-op
• Sort financial / work matters early – typical sick leave for major hepatobiliary surgery is 8-12 weeks
• Plan transport for follow-up appointments – they will be frequent in the first 6 months
• If you currently have an external drain (PTC), get comfortable with the practical care before discharge – your stoma/IR nurse will train you and family members
Surgical strategies – varies by subtype
Intrahepatic CCA (iCCA)
Liver resection following the same principles as for other liver cancers – anatomic or non-anatomic resection depending on tumour position and size. Increasingly performed laparoscopically or robotically for smaller, peripheral tumours. Regional lymphadenectomy of porta hepatis nodes is standard at most centres for staging purposes (controversial as a therapeutic intervention but informative for adjuvant therapy decisions).
Perihilar CCA (Klatskin)
The most surgically demanding hepatobiliary operation routinely performed. Typically involves:
• Major hepatectomy (right or left, often extended, depending on which side the tumour is on or extends into)
• Resection of the extrahepatic bile duct including the bifurcation
• Lymphadenectomy of porta hepatis and hepatoduodenal ligament
• Sometimes vascular resection and reconstruction (portal vein, occasionally hepatic artery)
• Reconstruction of biliary drainage from the remaining liver to a loop of small bowel (hepaticojejunostomy / Roux-en-Y)
Operative time is typically 6-10 hours. Hospital stay 10-14 days for uncomplicated cases. Performed only at high-volume HPB centres because of the technical complexity and the experience required for safe execution.
Distal CCA
Covered by the Whipple preparation guide on this site – same operation, same general considerations.
Liver transplantation for unresectable cholangiocarcinoma
Selected patients with locally-advanced unresectable perihilar cholangiocarcinoma may be candidates for liver transplantation under strict protocols (Mayo Clinic protocol; European emerging programmes). Requires neoadjuvant chemoradiation, exploratory laparotomy or laparoscopy to confirm no metastatic disease, then transplantation. 5-year survival in selected patients meeting full Mayo criteria is comparable to resection for resectable disease (~65%). Only available at specialist centres; eligibility is narrow.
Recovery expectations
More involved than recovery from CRLM or HCC resection because of the biliary reconstruction piece and the larger volume of liver resected for Klatskin tumours:
• Hospital stay: typically 7-10 days for iCCA resection; 10-14 days for Klatskin; 10-14 days for distal CCA Whipple
• Drains: most patients leave hospital with one or more abdominal drains in place to monitor for biliary leak (the most common post-op complication after hepatectomy with biliary reconstruction). Drains stay in for days to weeks depending on output and amylase content
• Days 1-7: early mobilisation, drain monitoring, gradual reintroduction of diet, watch for biliary leak (typically presents around day 3-7 as fever, abdominal pain, raised inflammatory markers, or increased drain output containing bile)
• Weeks 2-6: gradual recovery at home; return to office-style work usually 8-12 weeks; manual or physically demanding work 12–16 weeks
• Adjuvant chemotherapy (capecitabine per BILCAP) is the current standard for resected CCA – typically starts 6-10 weeks post-op, runs for 6 months. This will be discussed with you by your medical oncology team
Long-term outlook and ongoing surveillance
Surveillance after resection typically involves:
• Triphasic CT or MRI every 3-6 months for the first 2 years, 6-monthly to year 5, then annually
• CA 19-9 at each visit
• Adjuvant chemotherapy (capecitabine) per BILCAP, as above
• Molecular profiling on resection specimen if not already done – actionable mutations include FGFR2 fusions (iCCA), IDH1 mutations (iCCA), HER2 amplification (some CCA), MSI-high status (some CCA), BRAF V600E (rare)
• Long-term hepatology surveillance if you had primary sclerosing cholangitis (PSC) as the underlying risk factor
If recurrence occurs, it is most commonly within the first 2 years and most commonly in the liver remnant or in the porta hepatis. Modern systemic therapy combinations (durvalumab or pembrolizumab plus gemcitabine/cisplatin; targeted therapies for actionable mutations) have materially improved outcomes for recurrent disease compared to historic figures.
Resources
• AMMF – The Cholangiocarcinoma Charity (UK) – ammf.org.uk – the leading patient charity specifically for cholangiocarcinoma; comprehensive patient information, support line, peer networks. The single most useful patient resource if your diagnosis is CCA.
• Cholangiocarcinoma Foundation (US) – cholangiocarcinoma.org – large US-based patient charity with international reach; annual conference and active patient networks
• British Liver Trust – britishlivertrust.org.uk – broader liver disease charity that covers CCA among other conditions
• Irish Cancer Society – irishcancer.ie – patient support, information line, financial advice
• PSC Support (UK) – pscsupport.org.uk – for patients whose CCA arose on a background of primary sclerosing cholangitis
• Your local hepatobiliary unit’s patient information leaflets – ask
Evidence base
Key sources informing this article:
• Banales JM, Marin JJG, Lamarca A et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 2020;17(9):557–588.
• Bridgewater J, Galle PR, Khan SA et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 2014;60(6):1268–1289 (with subsequent ILCA / EASL updates — verify most recent version).
• Primrose JN, Fox RP, Palmer DH et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP). Lancet Oncol 2019;20(5):663–673.
• Oh DY, Ruth He A, Qin S et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer (TOPAZ-1). NEJM Evid 2022;1(8).
• Kelley RK, Ueno M, Yoo C et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966). Lancet 2023;401(10391):1853–1865.
• Abou-Alfa GK, Sahai V, Hollebecque A et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements (FIGHT-202). Lancet Oncol 2020;21(5):671–684.
• Zhu AX, Macarulla T, Javle MM et al. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation (ClarIDHy). JAMA Oncol 2021;7(11):1669–1677.
• Rea DJ, Heimbach JK, Rosen CB et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005;242(3):451–461 (Mayo protocol foundational paper).
• Melloul E, Hübner M, Scott M et al. Guidelines for perioperative care for liver surgery: ERAS Society recommendations. World J Surg 2016;40(10):2425–2440 (with updates).
• NICE — Cholangiocarcinoma management pathway and updates.
A final word
Cholangiocarcinoma is a hard diagnosis. The figures above are sobering and there is no point pretending otherwise. But the treatment landscape has improved meaningfully in the past five years – surgical patient selection is better, adjuvant chemotherapy is standard, modern systemic therapy works better than what came before, and molecular profiling can open targeted therapy options for selected patients. For the patients who are resectable and who complete the full treatment journey at a specialist centre, long-term survival is genuinely achievable.
The weeks before surgery for CCA are more intensive than for most other cancers — biliary drainage, nutritional rehabilitation, vigilance against cholangitis. The work matters. Patients who arrive at surgery with their bilirubin normalised, their nutrition optimised, no active cholangitis, and reasonable fitness recover better, have fewer complications, and are more likely to be able to receive adjuvant chemotherapy on schedule (which itself improves long-term outcomes).
If anything in this article does not match what your own team is telling you, follow your team’s advice for your particular situation. This is a general guide; your care is specific.
Reviewed by Mr Tom Gallagher, Consultant HPB Surgeon, St Vincent’s Healthcare Group, Dublin. Last updated 2 June 2026.